Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | PAM | P19021 | 2/20 | 0.52 |
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 5/20 | 0.48 |
| ▸ | PPARG | P37231 | 6/20 | 0.48 |
| ▸ | PPARD | Q03181 | 6/20 | 0.48 |
| ▸ | PPARA | Q07869 | 6/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | FABP4 | P15090 | 2/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.48 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1746235 | 1.00 | DGKA (0.57) | DGKALMNAPAMCES2CES1 | |
| SCHEMBL1747070 | 1.00 | DGKA (0.57) | DGKALMNAPAMCES2CES1 | |
| SCHEMBL1747414 | 1.00 | DGKA (0.57) | DGKALMNAPAMCES2CES1 | |
| SCHEMBL5077571 | 1.00 | DGKA (0.57) | DGKALMNAPAMCES2CES1 | |
| SCHEMBL1747375 | 1.00 | DGKA (0.57) | DGKALMNAPAMCES2CES1 | |
| SCHEMBL1747009 | 1.00 | DGKA (0.57) | DGKALMNAPAMCES2CES1 | |
| SCHEMBL1747371 | 1.00 | DGKA (0.57) | DGKALMNAPAMCES2CES1 | |
| SCHEMBL1747158 | 1.00 | DGKA (0.57) | DGKALMNAPAMCES2CES1 | |
| SCHEMBL1747104 | 1.00 | DGKA (0.57) | DGKALMNAPAMCES2CES1 | |
| SCHEMBL6554418 | 0.91 | DGKA (0.57) | DGKALMNAPAMCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3509706-B1 | METHOD FOR INCREASING LIPOLYSIS USING A COMPOSITION COMPRISING BIOACTIVE NELUMBO NUCIFERA (LOTUS) EXTRACT | ISP INVESTMENTS LLC (US) | 2021-11-03 | — | — | EP | claimed |
| EP-1948196-B1 | USE OF TETRAORGANOSILICON COMPOUNDS | SALAMA ZOSER B (DE) | 2012-12-26 | — | — | EP | claimed |
| US-20250161195-A1 | METHOD FOR OBTAINING PLANT EXTRACTS COMPRISING AN AUTOFERMENTATION STEP, COMPOSITIONS COMPRISING SUCH EXTRACTS AND COMETIC USES THEREOF | ISP INVESTMENTS LLC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20230364004-A1 | STABLE COMPOSITIONS CONTAINING A CANNABINOID | Angrow Company Limited (US) | 2023-11-16 | — | — | US | disclosed |
| US-11503840-B2 | Peptide and saccharide hydrolysate of cocoa beans, cosmetic compositions containing same, and cosmetic uses of same | ISP Investments LLC. (US) | 2022-11-22 | — | — | US | disclosed |
| CN-113747949-A | O/W type low viscosity emulsified composition containing adenosine phosphate | 大塚制药株式会社 | 2021-12-03 | — | — | CN | disclosed |
| CN-113710330-A | O/W type high viscosity emulsified composition containing adenosine phosphate | 大塚制药株式会社 | 2021-11-26 | — | — | CN | disclosed |
| EP-3509706-B1 | METHOD FOR INCREASING LIPOLYSIS USING A COMPOSITION COMPRISING BIOACTIVE NELUMBO NUCIFERA (LOTUS) EXTRACT | ISP INVESTMENTS LLC (US) | 2021-11-03 | — | — | EP | disclosed |
| US-11045669-B2 | Hydroalcoholic extract of Schinus molle, cosmetic compositions comprising the same and cosmetic uses thereof | ISP INVESTMENTS LLC (US) | 2021-06-29 | — | — | US | disclosed |
| US-20210106022-A1 | PEPTIDE AND SACCHARIDE HYDROLYSATE OF COCOA BEANS, COSMETIC COMPOSITIONS CONTAINING SAME, AND COSMETIC USES OF SAME | ISP Investments LLC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-10932477-B2 | Peptide and saccharide hydrolysate of cocoa beans, cosmetic compositions containing same, and cosmetic uses of same | ISP INVESTMENTS LLC (US) | 2021-03-02 | — | — | US | disclosed |
| EP-2384743-A1 | Siosomal formulation for intracellular delivery and targeting of therapeutic agents | Salama, Zoser B. (DE) | 2011-11-09 | — | — | EP | disclosed |
| WO-2011134675-A1 | CARRIER AND TARGETING SYSTEM COMPRISING A SIOSOMAL COMPOSITION FOR INTRACELLULAR DELIVERY AND TARGETING OF ACTIVE SUBSTANCE | SALAMA ZOSER B (DE) | 2011-11-03 | — | — | WO | disclosed |
| US-20100247578-A1 | CARRIER SYSTEM FOR BIOLOGICAL AGENTS CONTAINING ORGANOSILICON COMPOUNDS AND USES THEREOF | SALAMA ZOSER B | 2010-09-30 | — | — | US | disclosed |
| EP-1948196-A2 | USE OF TETRAORGANOSILICON COMPOUNDS | Salama, Zoser B. (DE) | 2008-07-30 | — | — | EP | disclosed |
| US-7241853-B2 | Printing processes employing intermediate transfer with molten intermediate transfer materials | XEROX CORPORATION (US) | 2007-07-10 | — | — | US | disclosed |
| WO-2007051462-A2 | USE OF TETRAORGANOSILICON COMPOUNDS | SALAMA ZOSER B (DE) | 2007-05-10 | — | — | WO | disclosed |
| US-5738857-A | Cosmetic compositions comprising organosiloxanes | WACKER-CHEMIE GMBH (DE) | 1998-04-14 | — | — | US | disclosed |
| EP-0483465-B1 | Long chain di(acyloxy)dialkylsilanes, di(acyloxy)diarylsilanes, di(acyloxy)dialkoxysilanes, and tetra(acyloxy)silanes, process for their preparation, their use for the preparation of vesicles, so produced vesicles and their use as vehicles for drugs | SALAMA ZOSER BOULIS DR (DE) | 1995-08-02 | — | — | EP | disclosed |
| EP-0483465-A1 | Long chain di(acyloxy)dialkylsilanes, di(acyloxy)diarylsilanes, di(acyloxy)dialkoxysilanes, and tetra(acyloxy)silanes, process for their preparation, their use for the preparation of vesicles, so produced vesicles and their use as vehicles for drugs | Salama, Zoser Boulis, Dr. (DE) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100247578-A1 | CARRIER SYSTEM FOR BIOLOGICAL AGENTS CONTAINING ORGANOSILICON COMPOUNDS AND USES THEREOF | EXOSC5, EXOSC9, SSB | DGKA 3104/4885LMNA 1390/4885PAM 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.